Which has preferable valuation & earnings, HUMAW or ALVOW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.12M N/A N/A N/A N/A Alvotech $491.95M N/A N/A N/A N/A

Is HUMAW or ALVOW more profitable?

Company Net Margins Return on Equity Return on Assets Humacyte N/A N/A N/A Alvotech N/A N/A N/A

Which has better earnings and valuation, HUMAW or APLMW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.12M N/A N/A N/A N/A Apollomics $8.50M N/A N/A N/A N/A

Is HUMAW or APLMW more profitable?

Company Net Margins Return on Equity Return on Assets Humacyte N/A N/A N/A Apollomics N/A N/A N/A

Which has preferable valuation and earnings, ARAV or HUMAW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aravive N/A N/A N/A -$0.90 N/A Humacyte $2.12M N/A N/A N/A N/A

Is ARAV or HUMAW more profitable?

Company Net Margins Return on Equity Return on Assets Aravive N/A N/A N/A Humacyte N/A N/A N/A

Which has preferable earnings and valuation, HUMAW or BIAFW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.12M N/A N/A N/A N/A bioAffinity Technologies $5.85M N/A N/A N/A N/A

Is HUMAW or BIAFW more profitable?

Company Net Margins Return on Equity Return on Assets Humacyte N/A N/A N/A bioAffinity Technologies N/A N/A N/A

Which has better earnings and valuation, HUMAW or BIVIW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.12M N/A N/A N/A N/A BioVie N/A N/A N/A N/A N/A

Is HUMAW or BIVIW more profitable?

Company Net Margins Return on Equity Return on Assets Humacyte N/A N/A N/A BioVie N/A N/A N/A

Humacyte (HUMAW) Competitors

$0.0009 0.00 (0.00%)

As of 08/26/2026

Compare

HUMAW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Humacyte stock or one of its competitors? Humacyte's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Humacyte compare to Alvotech?

Humacyte (NASDAQ:HUMAW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	N/A	N/A	N/A
Alvotech	N/A	N/A	N/A

In the previous week, Alvotech had 4 more articles in the media than Humacyte. MarketBeat recorded 4 mentions for Alvotech and 0 mentions for Humacyte. Alvotech's average media sentiment score of 0.20 beat Humacyte's score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Neutral
Alvotech	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.12M	N/A	N/A	N/A	N/A
Alvotech	$491.95M	N/A	N/A	N/A	N/A

Summary

Alvotech beats Humacyte on 3 of the 3 factors compared between the two stocks.

How does Humacyte compare to Apollomics?

Humacyte (NASDAQ:HUMAW) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Humacyte's average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company	Overall Sentiment
Humacyte	Neutral
Apollomics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	N/A	N/A	N/A
Apollomics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.12M	N/A	N/A	N/A	N/A
Apollomics	$8.50M	N/A	N/A	N/A	N/A

Summary

Apollomics beats Humacyte on 1 of the 1 factors compared between the two stocks.

How does Humacyte compare to Aravive?

Aravive (NASDAQ:ARAV) and Humacyte (NASDAQ:HUMAW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Aravive's average media sentiment score of 0.00 equaled Humacyte'saverage media sentiment score.

Company	Overall Sentiment
Aravive	Neutral
Humacyte	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Humacyte	N/A	N/A	N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Humacyte	$2.12M	N/A	N/A	N/A	N/A

Summary

Aravive beats Humacyte on 2 of the 3 factors compared between the two stocks.

How does Humacyte compare to bioAffinity Technologies?

Humacyte (NASDAQ:HUMAW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.12M	N/A	N/A	N/A	N/A
bioAffinity Technologies	$5.85M	N/A	N/A	N/A	N/A

In the previous week, bioAffinity Technologies had 1 more articles in the media than Humacyte. MarketBeat recorded 1 mentions for bioAffinity Technologies and 0 mentions for Humacyte. Humacyte's average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.88 indicating that Humacyte is being referred to more favorably in the media.

Company	Overall Sentiment
Humacyte	Neutral
bioAffinity Technologies	Negative

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	N/A	N/A	N/A
bioAffinity Technologies	N/A	N/A	N/A

Summary

bioAffinity Technologies beats Humacyte on 2 of the 3 factors compared between the two stocks.

How does Humacyte compare to BioVie?

Humacyte (NASDAQ:HUMAW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, BioVie had 3 more articles in the media than Humacyte. MarketBeat recorded 3 mentions for BioVie and 0 mentions for Humacyte. BioVie's average media sentiment score of 0.37 beat Humacyte's score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Neutral
BioVie	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	N/A	N/A	N/A
BioVie	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.12M	N/A	N/A	N/A	N/A
BioVie	N/A	N/A	N/A	N/A	N/A

Summary

BioVie beats Humacyte on 2 of the 3 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HUMAW vs. The Competition

Export

Metric	Humacyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	N/A	$3.89B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	N/A	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	N/A	15.45	10.46	6.33
Net Income	N/A	-$22.86M	$3.49B	$358.33M
7 Day Performance	N/A	-1.21%	0.59%	1.12%
1 Month Performance	N/A	-3.29%	-1.74%	-2.39%
1 Year Performance	N/A	37.74%	18.13%	5.35%

Humacyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HUMAW Humacyte	N/A	$0.00 flat	N/A	N/A	$0.00	$2.12M	N/A	150
ALVOW Alvotech	N/A	$0.30 flat	N/A	-66.1%	$0.00	$491.95M	N/A	4	Gap Up
APLMW Apollomics	N/A	$0.01 flat	N/A	-39.3%	$0.00	$8.50M	N/A	59	Positive News Upcoming Earnings
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
BIAFW bioAffinity Technologies	N/A	$0.70 flat	N/A	+296.0%	$0.00	$5.85M	N/A	10	News Coverage Positive News Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HUMAW) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humacyte (HUMAW) Competitors